SCHEMBL21665288

SCHEMBL21665288

CC(C)C1=CCN(C(=O)N(C(C)C)C(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
GRM1 Q13255 2/20 0.33
HRH1 P35367 1/20 0.33
GRM5 P41594 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
P2RX4 Q99571 2/20 0.33
P2RX1 P51575 1/20 0.33
P2RX3 P56373 1/20 0.33
P2RX7 Q99572 1/20 0.33
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
FKBP1A P62942 1/20 0.32
BCHE P06276 1/20 0.32
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
QDPR P09417 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17660297 0.85 MAPT (0.39) MEN1KMT2AKCNH2HRH3GRM1
SCHEMBL19454524 0.81 HRH3 (0.35) MEN1KMT2AKCNH2HRH3GRM1
SCHEMBL104852 0.81 QDPR (0.45) KMT2AKCNH2HRH3LMNAQDPR
SCHEMBL12030751 0.79 NAMPT (0.43) KCNH2HRH3
SCHEMBL19449815 0.79 PDK4 (0.34) MEN1KMT2AKCNH2HRH3GRM1
SCHEMBL15837090 0.77 CYP2C9 (0.36) MEN1KMT2AKCNH2HRH3GRM5
SCHEMBL18269035 0.77 POLB (0.44) TSHRSMN1; SMN2ALDH1A1
SCHEMBL12205461 0.77 HRH3 (0.46) MEN1KMT2AKCNH2HRH3P2RX4
SCHEMBL2603265 0.77 MEN1 (0.37) MEN1KMT2AKCNH2HRH3FKBP1A
SCHEMBL8178812 0.76 KDM4E (0.45) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919915-B2 Compounds as GPR119 agonists MANKIND PHARMA LTD. (IN) 2021-02-16 US disclosed
US-20200040006-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040006-A1 NOVEL COMPOUNDS AS GPR119 AGONISTS GPR119, GPR84, GPR65 MEN1 3564/4885KMT2A 3084/4885KCNH2 1112/4885
US-10919915-B2 Compounds as GPR119 agonists GPR119, GPR84, GPR65 MEN1 3286/4885KMT2A 3089/4885KCNH2 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.